Navigation Links
AXA Equitable Makes it Easier to Stop Ignoring Life Insurance
Date:11/5/2007

onal circumstances). The

interview is used to complete the

rest of the application.

Taking lots of time ROP Term(SM) Simplified Issue

underwriting uses a unique,

simplified application; a third-

party telephone interview and an

oral swab test. Because no

paramed or attending physician

statements are required, the

underwriting process results in

significant time savings.

AXA Equitable's Return of Premium Term(SM) (Policy forms 148-20, 148-25, 148-30 or state variations) is issued by and is a service mark of AXA Equitable Life Insurance Company, New York, NY. All guarantees are based on the claims-paying ability of AXA Equitable Life Insurance Company.

About AXA Equitable

AXA Equitable Life Insurance Company has been in business since 1859 and is a leading nationwide issuer of life insurance and annuity products. The company has over 11,000 employees and sales personnel and approximately 4.8 million policy/contract holders nationwide as of December 31, 2006. AXA Equitable Life Insurance Company, New York, N.Y., is one of the premier U.S. organizations providing life insurance and annuity products and services for the financial services market. Variable products are co-distributed by affiliates AXA Advisors, LLC, and AXA Distributors, LLC.

AXA Equitable's parent company, AXA Financial, Inc., is a member of the global AXA Group, a worldwide leader in financial protection and wealth management. AXA Group's operations are diverse geographically, with major operations in Western Europe, North America, and the Asia/Pacific regi
'/>"/>

SOURCE AXA Equitable
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. AXA Equitable Life Insurance Co. Hires William McDermott to Lead Corporate Retirement Planning Business
2. David Kahal Joins AXA Equitable as National Sales Manager
3. San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism
4. New Smart Technology Makes Patient Data Collection Easier, More Efficient
5. WeissComm Partners Makes 10 New Hires as It Wins New Accounts and Grows Existing Business
6. Independence Blue Cross Makes Music for Members Ears
7. A Place for Mom COO Makes Seattles 40 Under 40 List
8. Sesame Street Exhibition Makes Texas Premier at The Health Museum
9. Study makes progress in zoning in on biomarkers for better colon cancer treatment
10. New Online Tool Makes Enrollment in Blue Cross of California Easier
11. 1-800-PACK-RAT Makes a Splash During Annual Walk for Hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...r-old woman in British Columbia died a lonely deat...lbo, one of her sons, is hopeful that his mom’s de... care to the senior citizens. The hospital separa...ho was also being treated at the same hospital, Ko...
... in London are all set to make a go to build a sec...nada after losing a bid to build it in their own c...y be accommodated, according to David Sloman, pote...London. Shriners in Montreal are a bit apprehensiv...
...potato' burning bright in the hands of you could p...es.According to a long-term study of nearly 85 000...s’ //found that those with the highest potato inta... developing type 2 diabetes. Obese women, who are...
...udy appearing in online edition of Gut, a journal ...elly fat may raise the risk of gallstones in older...ominal circumference and waist-to- hip ratio were ...d risk of gallstones and gall bladder removal or c...
Other Medicine News:
(Date:10/8/2008)... Acceptance Will Reduce Animal Use in Cosmetics a...ewswire/ -- MatTek Corp. today announced,that resu...laboratory,"catch-up" validation study on MatTek,s...e test results demonstrated the required sensitivi... validated alternative to animal,testing for deter...
(Date:10/8/2008)...eview Zanolimumab Program to be Discontinued and H...the Results of its Portfolio Review; Zanolimumab ...duce the Number of E...Call/ -- Genmab A/S (OMX: GEN),announced today tha...HuMax-CD4(R)). In addition, as a result of a portf...
(Date:10/8/2008)... Findings Confirm Potency of Poly-ICR as Va...stCall/ -- Nventa Biopharmaceuticals,Corporation (...inical,studies using its proprietary Toll-like Rec... at the World Vaccine Congress 2008 in Lyon, Franc...ent vaccine adjuvant,targeting the Toll-like Recep...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus Lab..., today announced findings from its,development of...blood test,for irritable bowel syndrome (IBS). The...pression of particular biomarkers in blood samples...ion of these biomarkers,combined with a proprieta...
Breaking Medicine Technology:MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Spherix Receives NASDAQ Bid Price Deficiency Letter 6686 1Spherix Receives NASDAQ Bid Price Deficiency Letter 6686 2Simple Procedure Improves Male Fertility 24302 1Simple Procedure Improves Male Fertility 24302 2Simple Procedure Improves Male Fertility 24302 3Rock The Cradles Bad Boy Landon Brown Owes His Irresistible New Smile to Dr Michael Kosdon 24297 1Rock The Cradles Bad Boy Landon Brown Owes His Irresistible New Smile to Dr Michael Kosdon 24297 2Alameda County Hosts National Initiative to Reduce Health Disparities 24295 1Alameda County Hosts National Initiative to Reduce Health Disparities 24295 2
...could offer protection,for infants against Haemop... , , TORONTO, Canada, May 11, , 2007 &mdas...Phase II vaccine clinical study presented this wee... Annual Meeting in,Toronto, Canada. The new data s...ne holds potential to protect infants in the,first...
...WIRE)--May 14, 2007 - Oculus Innovative,Sciences, ...n,Technology was the subject of a poster presentat...EWMA) conference that was held in,Glasgow, Scotlan...esults About an Antimicrobial,Solution in the Trea... & Harding infection criteria to evaluate the,...
Other Medicine Technology:GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 2GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 3GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 4GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 5Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 2Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 3
Phaco chopper 1 mm fully cutting edge.
Round handle dull finish. For right handed surgeon.
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm.
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand.
Medicine Products: